rs2583988 — SNCA

SNCA rs2583988 — The Upstream Regulator Completing the PD Risk Haplotype

The SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) encodes the protein that aggregates into Lewy bodies — the pathological hallmark of Parkinson's disease; the gene harbors multiple independent risk variants spread across its genomic structure is bounded at its 5′ end by a regulatory landscape that controls how much alpha-synuclein the cell produces. rs2583988 sits approximately 1.4 kilobases upstream of the SNCA transcription start site — a "near gene-5" position that places it within the promoter-adjacent regulatory territory and within an intron of SNCA-AS1, the antisense long non-coding RNA that occupies the same chromosomal locus.

Unlike the other three SNCA variants in this database (rs356219, rs2736990, and rs11931074), rs2583988 has the weakest independent evidence of the group. Its primary clinical value is as the fourth component of the 4-SNP SNCA risk haplotype²² 4-SNP SNCA risk haplotype
The haplotype T-rs2583988 + G-rs356219 + C-rs2736990 + T-rs11931074 was identified in a 2017 Brazilian study as a high-risk combination, OR 2.51 for PD (Campelo et al. 2017) — the same haplotype documented in the studies that profiled its three companion SNPs. However, the TT homozygous genotype at rs2583988 does show a striking independent association (OR 12.20) in the Campelo cohort, and the T allele independently associates with cognitive impairment in PD patients.

The Mechanism

rs2583988 is classified as an upstream transcript variant³³ upstream transcript variant
A genomic variant in the region just 5′ of a gene's transcription start site, within or adjacent to promoter and enhancer elements that control gene transcription relative to SNCA. The position is within the 5′ regulatory zone that is known to control SNCA transcriptional output. Despite this location, a study measuring SNCA mRNA levels in peripheral blood mononuclear cells found no statistically significant correlation between rs2583988 genotypes and SNCA expression — suggesting that the variant may operate through a more nuanced regulatory mechanism rather than direct quantitative effects on transcript levels.

The most distinctive feature of rs2583988 is its unique association with the repressive histone mark H3K27me3⁴⁴ unique association with the repressive histone mark H3K27me3
H3K27me3 is placed by Polycomb repressive complex 2 (PRC2) and is associated with facultative heterochromatin — chromatin that can switch between active and silenced states at the SNCA upstream locus. Among the panel of SNCA PD risk variants studied in a 2019 epigenomics analysis, rs2583988 was the only variant showing this specific correlation. H3K27me3 marks so-called "bivalent chromatin" — regions poised to adopt either active or repressed states — suggesting that rs2583988 may influence SNCA expression through epigenetic chromatin remodeling rather than direct transcription factor binding disruption. The T risk allele may destabilize the repressive H3K27me3 state, potentially allowing SNCA to shift toward higher expression under specific cellular or environmental conditions.

The Evidence

The primary source for rs2583988's individual risk association is the 2017 Brazilian case-control study⁵⁵ 2017 Brazilian case-control study
Campelo et al. Variants in SNCA gene are associated with Parkinson's disease risk and cognitive symptoms in a Brazilian sample. Frontiers in Aging Neuroscience, 2017 (104 PD cases, 98 controls). The T allele was present in 28.8% of cases versus 19.3% of controls. The TT homozygous genotype showed a striking individual association of OR 12.20 (95% CI 1.52–97.58; p=0.018), and in multivariable logistic regression including environmental and clinical factors, the TT genotype predicted PD with OR 16.25 (95% CI 1.72–152.97; p=0.015). However, TT homozygotes were rare — only 11 cases and 1 control — making this estimate statistically unstable with very wide confidence intervals. The T allele was also significantly more common in PD patients with cognitive impairment (31%) than in controls (16%), yielding OR 2.39 (95% CI 1.25–4.58; p=0.010).

The same study identified the 4-SNP risk haplotype (T-rs2583988 + G-rs356219 + C-rs2736990 + T-rs11931074) with OR 2.51 (95% CI 1.37–4.58; p=0.003), establishing rs2583988 as an integral component of the highest-risk SNCA haplotype block.

A 2018 comprehensive meta-analysis⁶⁶ 2018 comprehensive meta-analysis
Zhang et al. A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease. Frontiers in Molecular Neuroscience, 2018 pooling data from 24,075 cases and 22,877 controls found rs2583988 T allele OR of 1.21 (95% CI 1.08–1.35; p=0.001) — statistically significant but below the p<1×10⁻⁵ threshold used to designate the strongest SNCA variants. The most recent 2025 systematic review⁷⁷ 2025 systematic review
Mohammadi et al. Common SNCA Genetic Variants and Parkinson's Disease Risk: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2025 across 27 studies found that rs2583988 showed only marginal significance under the allelic model, with the effect losing significance after sensitivity analysis and correction for publication bias — the weakest independent signal among the four haplotype-component variants. The evidence for rs2583988 as an independent PD risk factor is therefore rated as emerging.

A 2009 Saskatchewan cohort study⁸⁸ 2009 Saskatchewan cohort study
Heckman et al. Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. Movement Disorders, 2009 (452 PD cases, 245 controls) found only a trend-level association between rs2583988 variation and rapid PD progression — not reaching statistical significance as an individual susceptibility marker.

Practical Actions

Given the emerging-level independent evidence and the tight linkage of rs2583988 with its three companion SNPs in the risk haplotype, the practical actions for T-allele carriers mirror those of the other SNCA risk variants: protecting the cellular environment against the downstream consequences of elevated alpha-synuclein, regardless of which upstream regulatory mechanism is responsible.

For TT homozygotes — who showed the most striking individual association in the Campelo study — the priority is the same neuroprotective strategy applied to the other high-risk SNCA genotypes: mitochondrial support with ubiquinol, autophagy promotion through aerobic exercise, manganese avoidance, and earlier neurological monitoring. The cognitive impairment association (OR 2.39 in PD patients with the T allele) adds weight to monitoring cognitive trajectory.

The T allele's extremely low frequency in East Asian populations (~1%) means this variant has almost no clinical relevance in that ancestry group — its clinical significance is concentrated in European populations where ~25% carry at least one T allele.

Interactions

rs2583988 is the 5′-upstream component of the 4-SNP SNCA risk haplotype⁹⁹ 4-SNP SNCA risk haplotype alongside rs356219 (3′ regulatory), rs2736990 (intron 4), and rs11931074 (3′ UTR). These four variants occupy different linkage disequilibrium blocks across the SNCA locus and carry independent risk information. The combined haplotype T+G+C+T has OR 2.51 — substantially higher than any single variant alone — confirming that multi-SNP SNCA risk assessment is more informative than evaluating any single variant in isolation.

The companion variants are each independently profiled in this database: rs356219 (strong independent evidence, SNCA expression elevation), rs2736990 (strong independent evidence, intron 4 regulatory), and rs11931074 (strong independent evidence, 3′ UTR mRNA stability). Together they provide comprehensive coverage of the SNCA PD risk locus.